Evelo Biosciences initiated with an Outperform at Cowen. Cowen analyst Chris Shibutani initiated Evelo Biosciences with an Outperform rating as he believes its innovate monoclonal microbials have the potential to emerge as a a novel class of medicines for unmet needs in a range of serious diseases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.